January 16, 2019
Although, unsteady pricing and upcoming rising LPS (loss-per-share) earnings will test investors
Are you willing to BUY into equity risk pre-earnings call and a sector that languishes in short-termism?
Pre-open indication: 1 BUY, 1 SELL and 3 TRADEs
One of my focuses is indication analysis. An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation. The sole provision is that it provides insight to provide some vision into a likely course of action.
I answer one question, in which company should investors put, keep and commit their money!
January 16, 2019
STML closed up at $0.86 (+9.47%) to $9.94
Expected gross proceeds to Stemline are $80 million.
Due to demand, this offering was upsized from the previously announced 6,600,000 shares.
BUY
January 16, 2019
Advancers of the Advance/Decline Line (A/DL) are slipping while volume stats are very low, 11 out of the 23 upside had higher (than the 3 month average) volume and 3 out of the 20 downside experienced greater volume (than the 3 month average) volume
Pre-open Indication: 4 HITs and 1 MISS
Out and about: Osiris (OSIR +$1.09 or +8.07% to $14.59) a settlement on behalf of investors who purchased shares between May 12, 2014 and November 16, 2015 is reached. The class action alleged violations of the federal securities laws. Named as defendants were Osiris, Lode Debrabandere, Gregory Law and Philip R. Jacoby, Jr. Settlement is pending final approval.
Outspoken and just right again!
RMi outlines preludes and aftermaths defining the daily dose of facts, investment thesis and objectivity!
January 16, 2019
STML closed up at $0.86 (+9.47%) to $9.94 Expected gross proceeds to Stemline are $80 million. Due to demand, this offering was upsized from the previously announced 6,600,000 shares. STML has also granted the underwriters a 30-day option to purchase up to 1,333,333 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. BUY
January 15, 2019
ALNY closed down -$3.57 or -4.25% to $80.45 after closing down -$5.10 on Monday The gross proceeds to ALNY from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $387.5 M. BUY
January 11, 2019
RMi is the source investors and traders need – it’s more than opinion; the facts and truth need to be recognized! I post about “indication intelligence” devoting my time to collection and analysis of information for insight into sector vulnerabilities and strengths. My writing is “that warning analysis is NOT a commodity. However, there are times, when the likelihood of conclusions are inescapable! http://www.regmedinvestors.com/create-account
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
